Tuesday, Tiziana Life Sciences Ltd. (TLSA) announced that the FDA has accepted its submission for Fast Track Designation for intranasal foralumab to treat non-active, secondary-progressive multiple sclerosis or na-SPMS.
The company stated that the Fast Track Designation application incorporated data from animal studies and clinical insights from the Intermediate-Sized Patient Population Expanded Access initiative. This information demonstrated maintenance of disease stability in all ten patients within six months and a notable decrease in fatigue scores for 70% of the patients.
Foralumab, a human anti-CD3 monoclonal antibody, is a potential biological drug that attaches to the T cell receptor aiming to decrease inflammation by adjusting T cell activity, consequently dampening effector characteristics in different types of immune cells.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.